Anthem Bioscienc

{
  "main_header": {
    "sid": 10039665,
    "name": "Anthem Bioscienc",
    "stock_name": "Anthem Bioscienc",
    "full_name": "Anthem Biosciences Ltd",
    "name_url": "stocks-analysis/anthem-bioscienc",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "600.70",
    "chg": 8.65,
    "chgp": "1.46%",
    "dir": 1,
    "prev_price": "592.05",
    "mcapval": "33,764.00 Cr",
    "mcap": "Large Cap",
    "scripcode": 544449,
    "symbol": "ANTHEM",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0CZ201020",
    "curr_date": "Jan 28",
    "curr_time": "",
    "bse_nse_vol": "1.21 lacs",
    "exc_status": "Active",
    "traded_date": "Jan 28, 2026",
    "traded_date_str": "2026 01 28",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/anthem-bioscienc-10039665-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "When is the next results date for Anthem Biosciences Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-anthem-biosciences-ltd-3808429",
        "imagepath": "",
        "date": "2026-01-28 23:16:55",
        "description": "The next results date for Anthem Biosciences Ltd is scheduled for February 5, 2026...."
      },
      {
        "title": "How has been the historical performance of Anthem Bioscienc?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-anthem-bioscienc-3683766",
        "imagepath": "",
        "date": "2025-11-09 22:50:20",
        "description": "Answer:\nThe historical performance of Anthem Bioscienc shows significant growth in various financial metrics from March 2024 to March 2025.\n\nBreakdown:\nAnthem Bioscienc reported net sales of 1,844.55 Cr in March 2025, an increase from 1,419.37 Cr in March 2024. The total operating income also rose to 1,844.55 Cr from 1,419.37 Cr, while total expenditure increased to 1,173.72 Cr from 914.40 Cr. This led to an operating profit (PBDIT) of 756.56 Cr, up from 568.67 Cr the previous year. Profit before tax reached 656.87 Cr, compared to 477.32 Cr in the prior year, resulting in a profit after tax of 451.26 Cr, which was higher than 367.31 Cr in March 2024. The earnings per share increased to 8.07 from 6.57, and the operating profit margin improved slightly to 36.37% from 35.58%. On the balance sheet, total assets grew to 2,789.64 Cr from 2,356.72 Cr, while total liabilities also increased to 2,789.64 Cr from 2,35..."
      }
    ],
    "total": 5,
    "sid": "10039665",
    "stock_news_url": "https://www.marketsmojo.com/news/anthem-biosciences-10039665"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "27-Jan-2026",
      "details": "Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that an Earnings Conference Call to discuss the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31 2025 is scheduled on Thursday February 05 2026 at 02:30 PM IST/ 04:00 AM USA / 09:00 AM UK / 05:00 PM SGT/HKT.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Board Meeting Intimation For Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025",
      "datetime": "27-Jan-2026",
      "details": "Anthem Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2026 inter alia to consider and approve This is to inform you that pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 a meeting of the Board of Directors of Anthem Biosciences Limited (the Company) is scheduled to be held on Thursday February 05 2026 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31 2025.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "27-Jan-2026",
      "details": "Revised Earnings Conference Call to discuss the unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "05 Feb 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

When is the next results date for Anthem Biosciences Ltd?

2026-01-28 23:16:55

The next results date for Anthem Biosciences Ltd is scheduled for February 5, 2026....

Read full news article

How has been the historical performance of Anthem Bioscienc?

2025-11-09 22:50:20

Answer: The historical performance of Anthem Bioscienc shows significant growth in various financial metrics from March 2024 to March 2025. Breakdown: Anthem Bioscienc reported net sales of 1,844.55 Cr in March 2025, an increase from 1,419.37 Cr in March 2024. The total operating income also rose to 1,844.55 Cr from 1,419.37 Cr, while total expenditure increased to 1,173.72 Cr from 914.40 Cr. This led to an operating profit (PBDIT) of 756.56 Cr, up from 568.67 Cr the previous year. Profit before tax reached 656.87 Cr, compared to 477.32 Cr in the prior year, resulting in a profit after tax of 451.26 Cr, which was higher than 367.31 Cr in March 2024. The earnings per share increased to 8.07 from 6.57, and the operating profit margin improved slightly to 36.37% from 35.58%. On the balance sheet, total assets grew to 2,789.64 Cr from 2,356.72 Cr, while total liabilities also increased to 2,789.64 Cr from 2,35...

Read full news article

View All News